The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 9 of the 27 sources its claims cite were checked for support.
Nitazenes: review of comparative pharmacology and antagonist action
Open accessAbstract
Introduction Nitazenes are a class of potent synthetic opioids that have emerged in illicit drug markets and have been identified in combination with other opioids in cases of poisoning and fatalities. Originally developed in the 1950s, these compounds were abandoned due to their high toxicity and unfavourable therapeutic index. Recent reports indicate that nitazenes exhibit a wide range of potencies, with some exceeding that of fentanyl. Understanding the pharmacological and toxicological profiles of nitazenes is critical for public health and clinical management. This review synthesizes literature on the pharmacology, toxicity, and antagonist action of nitazenes, particularly their response to naloxone.Methods A comprehensive literature review was conducted using EMBASE, Ovid MEDLINE(R), APA PsycInfo, Scopus, and Web of Science up to 26 July 2024. The main search terms used were: “nitazen*”, “2-benzylbenzimidazole”, “aminoisotonitazene” OR “butonitazeneor clonitazene” OR “desnitazene” OR “etodesnitazene” OR “etonitazene” OR “flunitazene” OR “isotonitazene” OR “metodesnitazene” OR “metonitazene” OR “protonitazene”. Inclusion criteria encompassed in vitro and animal studies, post-mortem toxicology, clinical trials, and case reports on nitazene poisoning. Data regarding naloxone dosing in confirmed cases of nitazene poisoning were also analyzed.Results We identified 1,383 studies, and after removing duplicates, 557 abstracts were screened. Based on the eligibility criteria, 78 articles underwent full-text screening, and 35 were included in the final review. Nitazenes exhibit variability in potency and toxicity. In vitro studies suggest that their receptor affinity and potency often surpass those of both morphine and fentanyl. Real-world data indicate that in vivo potency is often lower than experimental findings. Case reports and clinical series indicate that naloxone remains an effective antidote for nitazene poisoning. A median dose of parenteral naloxone 1.20 mg effectively reversed poisoning, with a median dose of 0.8 mg in the pre-hospital setting. However, a subset of patients received prolonged naloxone infusions due to the persistence of opioid effects. Six out of 30 patients were treated with naloxone infusions. This ratio is higher than that reflected in current clinical guidelines, in which shorter observation time is deemed sufficient. Post-mortem toxicological analyses reveal highly variable nitazene concentrations, with overlap with those concentrations found in patients. This complicates the establishment of lethal thresholds. In several cases, nitazene metabolites were detected in isolation, suggesting independent pharmacological activity or alternative routes of administration. Additionally, nitazene poisoning often involves polysubstance use, further complicating diagnosis and management.Discussion Data on nitazene potency in humans are scarce. Nitazenes are a heterogeneous group with very high experimental potency compared to morphine. The potency in in vivo outcome studies in humans is far lower than that in in vitro studies. Post-mortem concentrations of many nitazenes are similar to the post-mortem concentrations of fentanyl and indicate a similar potency. Treatment of nitazene poisoning should follow the guidelines for opioid poisoning, that is, instituting airway management and administering naloxone. All cases reviewed had several opioids and other sedating drugs in addition to nitazenes in their analytical workup. The median parenteral dose for successful reversal of features was 1.20 mg. This finding provides reassurance that naloxone is effective for the treatment of poisoning due to nitazene as well as other potent opioids.Conclusions Nitazenes represent an emerging public health challenge due to their high potency, unknown pharmacokinetics, and increasing presence in illicit drug supplies. While naloxone is effective in reversing nitazene poisoning, cases of prolonged toxicity suggest the need for extended monitoring and repeated naloxone dosing. The findings of this review highlight the importance of enhanced drug surveillance, improved clinical awareness, and the development of targeted harm reduction strategies, including the potential for novel opioid antagonists with prolonged efficacy. Future research should focus on defining nitazene receptor kinetics, post-mortem redistribution effects, and optimizing naloxone administration protocols for these emerging synthetic opioids.
Overview
CoChat Summary
TL;DR
This systematic review synthesizes nitazene pharmacology, toxicity, and naloxone reversal, finding very high in vitro potency but substantially lower human in vivo potency and highly variable post-mortem concentrations. Naloxone remains effective, with a median parenteral reversal dose of 1.20 mg, though 6 of 30 patients required prolonged naloxone infusions.
Key findings
- In vitro potency often exceeds morphine and fentanyl: metonitazene and isotonitazene exceeded fentanyl by approximately 6-fold and 125-fold, respectively; etonitazene’s in vitro antinociceptive potency was 1,000 times morphine, but its human euphoric effect was 80–120 times morphine. Metonitazene was 100 times morphine in vitro but only 10 times morphine in humans; clonitazene was 3 times morphine in vitro but one-third to one-half morphine in humans.
- Among 30 analytically confirmed nitazene poisoning cases, median total parenteral naloxone dose was 1.20 mg (IQR 0.80–1.94 mg; n = 29); parenteral-route median was 0.80 mg (IQR 0.40–1.20 mg; n = 25). Six of 30 patients received prolonged naloxone infusions, and two of 30 died after cardiac arrest at presentation.
- Post-mortem nitazene concentrations were variable and overlapped with patient concentrations: isotonitazene median 1.2–1.7 µg/L (range 0.4–9.5 µg/L), metonitazene median 3.8–6 µg/L (range <0.5–33 µg/L), and protonitazene peripheral blood 0.1–25 µg/L, with one central blood case at 1,400 µg/L. Fentanyl post-mortem median was 16 µg/L (range 1.3–200 µg/L; n = 824), and carfentanil median was 0.098 µg/L (range 0.01–2 µg/L; n = 262).
- The review identified 1,383 studies; after duplicate removal, 557 abstracts were screened, and 35 articles were included in the final review. Nitazene poisoning often involved polysubstance use, and nitazene metabolites were sometimes detected in isolation.
Methods
- Systematic literature search of EMBASE, Ovid MEDLINE, APA PsycInfo, Scopus, and Web of Science, plus citation searching and non-indexed sources, through 26 July 2024; search terms included “nitazen*” and individual nitazene names; articles in English and German; no search filters; Covidence and PRISMA used.
- Inclusion covered in vitro and animal studies, post-mortem toxicology, clinical trials, case reports/case series, and policy documents; articles were included if they contained human nitazene concentrations, in vitro potency, or antagonism data, and excluded if limited to animals, lacked concentration data, or concerned analytical methodology. Two authors screened abstracts, all authors contributed to full-text review, and conflicts were resolved by discussion.
- Descriptive synthesis; naloxone doses were summed and bioavailable doses calculated assuming 50% intranasal and 90% intramuscular bioavailability; analyses used Microsoft Excel and SigmaPlot 15.0, with normality assessed by Shapiro-Wilk and results reported as median and IQR unless otherwise specified.
Limitations
- Stated: no randomized trials addressed the review’s objectives; many included studies used in vitro or post-mortem data, limiting clinical generalizability; no minimum standards or standardized formats exist for reporting naloxone dosing, routes, or timing between doses, making collation across case reports/series challenging.
- Evident from the text: human potency data are scarce, samples were small case reports/series that may not represent a native population, post-mortem redistribution and interindividual tolerance complicate concentration comparisons, most poisonings involved other psychoactive drugs, and no receptor kinetics data for nitazenes were found.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 9 Not valid · 10 Not checked · 35 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“This is highlighted for morphine, as its serum concentrations were significantly higher in patients receiving intravenous morphine for cancer-related pain than in all morphine-positive post-mortem cases in another study [14,47].”
§ Nitazenes: review of comparative pharmacology and antagonist action > Comparative toxicology
What the sources say
- Not checked — no full text of the sourcecites [14] 14. Krotulski AJ, Papsun DM, walton Se, et al. Metonitazene in the United States-Forensic toxicology assessment of a potent new synthetic opioid using liquid chromatog- raphy mass spectrometry. Drug Test Anal. 2021;13(10): 1697-1711. doi: 10.1002/dta.3115. source
- Could not verifycites [47] 47. Saari Ti, Strang J, Dale O. Clinical pharmacokinetics and pharmacodynamics of naloxone. Clin Pharmacokinet. 2024;63(4):397-422. doi: 10.1007/s40262-024-01355-6. sourceExperimental — accuracy not yet measured
The Modeling Studies section discusses morphine-induced respiratory depression in healthy volunteers, not serum concentrations in patients with cancer-related pain. The Simulation of Clinical Scenarios section discusses post-mortem concentrations of fentanyl, not morphine. Searches for the cancer-pain and post-mortem morphine comparison found no passage reporting the claimed difference or its statistical significance; page numbers were not available in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, interindividual tolerance to different opioids varies greatly from opioid-naive patients to patients who use opioids regularly.”
§ Nitazenes: review of comparative pharmacology and antagonist action > Comparative toxicology
What the sources say
- Not checked — no full text of the sourcecites [14] 14. Krotulski AJ, Papsun DM, walton Se, et al. Metonitazene in the United States-Forensic toxicology assessment of a potent new synthetic opioid using liquid chromatog- raphy mass spectrometry. Drug Test Anal. 2021;13(10): 1697-1711. doi: 10.1002/dta.3115. source
- Partly supportedcites [47] 47. Saari Ti, Strang J, Dale O. Clinical pharmacokinetics and pharmacodynamics of naloxone. Clin Pharmacokinet. 2024;63(4):397-422. doi: 10.1007/s40262-024-01355-6. sourceExperimental — accuracy not yet measured
The Clinical Trials section (Dosing, Safety, and Efficacy; page unavailable) discusses patients with opioid tolerance, and the Discussion (page unavailable) describes individual variability in naloxone pharmacokinetics. Neither passage establishes that tolerance to different opioids varies greatly between opioid-naive patients and regular opioid users; the variability described concerns naloxone, not opioid tolerance. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Jadhav et al. [51] reviewed the metabolism of butonitazene, isotonitazene, and protonitazene in vitro and identified multiple metabolic pathways for all three compounds.”
§ Nitazenes: review of comparative pharmacology and antagonist action > Comparative toxicology
What the sources say
- Could not verifycites [51] 51. eide D, Gjersing L, Danielsen Aw, et al. Heightened mortality risk after a non-fatal opioid overdose: risk factors for mortality in the week following emergency treatment. Addiction. 2024;119(12):2131-2138. doi: 10.1111/add.16632. sourceExperimental — accuracy not yet measured
The Study design section describes a prospective observational study of patients treated for opioid overdose by Oslo emergency medical services, not an in vitro metabolism study. Searches for butonitazene, isotonitazene, protonitazene, metabolic pathways, and Jadhav found no passage in our copy addressing the claim; page numbers were not available. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Calello et al. [25] and Amaducci et al. [42,43] reported reversal doses ranging from 0.08 mg to 2.00 mg”
§ Nitazenes: review of comparative pharmacology and antagonist action > Antagonism
What the sources say
- Not checked — no full text of the sourcecites [25] 25. Krotulski AJ, Papsun DM, Kacinko SL, et al. isotonitazene quantitation and metabolite discovery in authentic fo- rensic casework. J Anal Toxicol. 2020;44(6):521-530. doi: 10.1093/jat/bkaa016. source
- Partly supportedcites [42] 42. Calello DP, Aldy K, Jefri M, et al. identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in pa- tients with suspected opioid overdose. Clin Toxicol (Phila). 2022;60(9):1067-1069. doi: 10.1080/15563650.2022.2084406. sourceExperimental — accuracy not yet measured
The Abstract Results report initial naloxone doses of 0.08 mg IV and 2 mg intranasally, supporting both stated endpoints for Calello et al. But the same passage also reports an 8 mg intranasal dose, so 0.08–2.00 mg does not describe the full range in this paper. This verdict addresses Calello et al., not the separately cited Amaducci papers. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [43] 43. Pucci M, Hudson S, Hill SL, et al. Severe toxicity involv- ing N-pyrrolidino etonitazene in the United Kingdom-a case report. Clin Toxicol (Phila). 2022;60(4):533-534. doi: 10.1080/15563650.2021.1979235. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data on nitazene potency in humans are scarce.”
§ Nitazenes: review of comparative pharmacology and antagonist action > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
31 more claims
Create a free account to see all 56 claims and every source verdict.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 7
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, potency estimates vary according to the experimental endpoint evaluated, including receptor binding affinity, intracellular signaling assays, antinociceptive testing, and behavioral models. Consequently, potency rankings should be interpreted as approximations rather than absolute values [18].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Metonitazene appears somewhat less potent than isotonitazene and etonitazene but remains capable of producing profound opioid toxicity at very low doses [18].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while isotonitazene is estimated at ~500 times the potency of morphine [12,34].”
From Nitazenes: The Emergence of a Potent Synthetic Opioid Threat (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the rapid metabolism of nitazenes and the involvement of polymorphic CYP enzymes may influence individual susceptibility to intoxication and addiction, while also complicating toxicological and forensic analysis [6,12,35,42].”
From Nitazenes: The Emergence of a Potent Synthetic Opioid Threat (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Protonitazene is a highly potent nitazene analog which also produces its main mechanism of action through being a mu opioid receptor agonist [18].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [18]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nitazenes: review of comparative pharmacology and antagonist action > Abstract
“All cases reviewed had several opioids and other sedating drugs in addition to nitazenes in their analytical workup.”
§ Nitazenes: review of comparative pharmacology and antagonist action > Naloxone dosing
“After toxicological analysis, single opioid drugs were detected in three cases, while a combination of nitazenes, fentanyl analogues, or 6-monoacetylmorphine were detected in the remaining cases.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nitazenes: review of comparative pharmacology and antagonist action > In vitro and animal studies
“Blanckaert et al. [9] and DeLuca et al. [10] reported that isotonitazene has high mu-opioid receptor potency and efficacy.”
§ Nitazenes: review of comparative pharmacology and antagonist action > References
“8. Blanckaert P, Cannaert A, van Uytfanghe K, et al. Report on a novel emerging class of highly potent benzimid- azole NPS opioids: chemical and in vitro functional characterization of isotonitazene.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nitazenes: review of comparative pharmacology and antagonist action > Abstract
“Based on the eligibility criteria, 78 articles underwent full-text screening, and 35 were included in the final review.”
§ Nitazenes: review of comparative pharmacology and antagonist action > Results
“Based on the eligibility criteria, 80 articles underwent full-text screening, and 35 were included in the final review.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nitazenes: review of comparative pharmacology and antagonist action > Conclusion
“5,599.9 (100-769,178),”
§ Nitazenes: review of comparative pharmacology and antagonist action > Samples from patients and those driving under the influence of drugs
“Morphine concentrations were in the range of 100 µg/L to 769 µg/L in 24 patients with cancer who received intravenous morphine in a hospital setting [14].”
Citations
Cites
Lavonas, E. J., Akpunonu, P. D., Arens, A. M., Babu, K. M., Cao, D., Hoffman, R. S., Hoyte, C. O., Mazer-Amirshahi, M. E., Stolbach, A., St-Onge, M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001161 · Cited by 189 · cited 2×
“This includes recognizing symptoms, alerting emergency services, physical stimulation, addressing the airway and ventilation in a peri-arrest patient is of the highest priority, and, if needed, commencing cardiopulmonary resuscitation and naloxone administration [55].”
Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
Isotonitazene Quantitation and Metabolite Discovery in Authentic Forensic Casework
Krotulski, A. J., Papsun, D. M., Kacinko, S. L., & Logan, B. K. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa016 · Cited by 146 · cited 1×
“The median post-mortem isotonitazene concentration was between 1.2 µg/L and 1.7 µg/L (range: 0.4– 9.5 µg/L) and skewed toward the lower end of the range [11,26–28].”
InfluentialDARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00037 · Cited by 141
Algera, M. H., Kamp, J., van der Schrier, R., van Velzen, M., Niesters, M., Aarts, L., Dahan, A., & Olofsen, E. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.12.023 · Cited by 123 · cited 1×
“…reversal depends on several factors: the dose of naloxone administered and its elimination half-life, the k off value of the opioid that requires reversal, and the potency of naloxone in dissociating the opioid from the mu-opioid receptor, which depends on the K D (dissociation constant) [49,50].”
Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review
Kim, H. K., & Nelson, L. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1037274 · Cited by 116
Blanckaert, P., Cannaert, A., Van Uytfanghe, K., Hulpia, F., Deconinck, E., Van Calenbergh, S., & Stove, C. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2738 · Cited by 116
Streisand, J. B., Bailey, P. L., Maire, L. L., Ashburn, M. A., Tarver, S. D., Varvel, J. R., & Stanley, T. H. (1993) · Anesthesiology · doi:10.1097/00000542-199304000-00003 · Cited by 101 · cited 1×
“Nitazenes may also induce skeletal muscle rigidity (stiff/wooden chest), similar to other potent opioids [6].”
Walton, S. E., Krotulski, A. J., & Logan, B. K. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab117 · Cited by 92
Krotulski, A. J., Papsun, D. M., Walton, S. E., & Logan, B. K. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3115 · Cited by 91 · cited 1×
“There is some overlap between the cases reported for metonitazene, with the reported median ranging from 3.8 µg/L to 6 µg/L [11,15,27,33].”
Influential
Research works printed but not linked: 1
- 10.1515/cclm-2023-136 · doi:10.1515/cclm-2023-136
Cited by
Clinical Experiences With the Nitazene Class of Synthetic Opioids: A Cohort Study
Roberts, D. M., Tisdell, B., Sajeev, M. F., Jiranantakan, T., Harvey, C., & Brown, J. A. (2025) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2025.06.619 · Cited by 20
Nitazenes: The Emergence of a Potent Synthetic Opioid Threat
Pereira, J. R. P., Quintas, A., & Neng, N. R. (2025) · Molecules · doi:10.3390/molecules30193890 · Cited by 21
“This contrasts with current guidelines for shorter observation periods for other opioids [12].”
InfluentialDugues, P., Rabai, A., Chenorhokian, S., Pfau, G., Cherki, S., Bellouard, M., Alvarez, J. C., & Larabi, I. A. (2025) · Toxicologie Analytique et Clinique · doi:10.1016/j.toxac.2025.07.002 · Cited by 6
Analytical approaches for the identification and quantitation of nitazenes: a review
Mandrioli, R., Protti, M., Lecce, R. D., & Mercolini, L. (2025) · Journal of Chromatography Open · doi:10.1016/j.jcoa.2025.100305 · Cited by 7
Freestone, J., Siefried, K. J., Peacock, A., Fletcher, K., Barratt, M. J., Sutherland, R., Ezard, N., Doumany, J., MacDonald, H., Kypri, S., et al. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104946 · Cited by 8
Metadata
- Authors
- Stangeland, M., Dale, O., & Skulberg, A. K.
- Affiliations
- Haukeland University Hospital (NO)
- Norwegian University of Science and Technology (NO)
- Oslo University Hospital (NO)
- Corresponding author
- Skulberg, Arne Kristian
- Venue
- Clinical Toxicology
- Publisher
- Informa UK Limited
- Published
- 2025-05-27
- Volume
- 63
- Issue
- 6
- Pages
- 393-406
- ISSN
- 0009-9309 (ISSN-L)
- 1556-3650
- 1556-9519
- OpenAlex
- W4410779225
- Semantic Scholar
- c1b8fab05ef9f59f174447383b3bfbc1590b0eca
- Cited by
- 34
- References
- 53
- Citations by year
- 2026: 22 · 2025: 12
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Toxicology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Haukeland University Hospital and Oslo University Hospital, Norway and the Norwegian University of Science and Technology
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- nitazenes, synthetic opioids, opioid toxicity, naloxone, naloxone antagonism, opioid receptor affinity, opioid potency, postmortem toxicology, illicit drug markets, combination therapy, etonitazene
- MeSH terms
- Analgesics, Opioid, Animals, Humans, Naloxone, Narcotic Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nitazenes: review of comparative pharmacology and antagonist action. https://app.cochat.ai/papers/10.1080/15563650.2025.2504133
- The paper
- Stangeland, M., Dale, O., & Skulberg, A. K. (2025). Nitazenes: review of comparative pharmacology and antagonist action. Clinical Toxicology. https://doi.org/10.1080/15563650.2025.2504133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.